tiprankstipranks
Neurocrine (GB:0K6R)
LSE:0K6R

Neurocrine Stock Price & Analysis

0 Followers

0K6R Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$105.38
Volume0.00
Average Volume (3M)405.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$648.30M
Total Debt (Recent Filing)$508.00M
P/E RatioN/A
Beta0.02
Next EarningsNov 01, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding95,639,321
R-Squared0.02
Standard Deviation0.13
10 Day Avg. Volume17
30 Day Avg. Volume405
P/B Ratio6.94
P/S Ratio8.10
P/CF Ratio61.00
P/FCF Ratio74.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside9.84% Upside
Rating ConsensusModerate Buy
Alpha0.01
Number of Analyst Covering13


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

0K6R FAQ

What was Neurocrine’s price range in the past 12 months?
Currently, no data Available
What is Neurocrine’s market cap?
Currently, no data Available
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Nov 01, 2022 which is in 37 days.
    How were Neurocrine’s earnings last quarter?
    Neurocrine released its earnings results on Aug 04, 2022. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.619 by -$0.799.
      Is Neurocrine overvalued?
      According to Wall Street analysts Neurocrine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Neurocrine pay dividends?
        Neurocrine does not currently pay dividends.
        What is Neurocrine’s EPS estimate?
        Neurocrine’s EPS estimate is $0.8.
          How many shares outstanding does Neurocrine have?
          Currently, no data Available
          What happened to Neurocrine’s price movement after its last earnings report?
          Neurocrine reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.619. Following the earnings report the stock price went up 10.912%.
            Which hedge fund is a major shareholder of Neurocrine?
            Among the largest hedge funds holding Neurocrine’s share is Deerfield Management Company, LP. It holds Neurocrine’s shares valued at 196M.

              ---

              Neurocrine Stock Analysis

              Smart ScoreOutperform
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              10

              Analyst Consensus

              Moderate Buy
              Average Price Target: $115.75

              Blogger Sentiment

              Bullish
              GB:0K6R Sentiment 100% Sector Average 69%

              Insider Transactions

              N/A
              Currently Not Enough Data Available

              News Sentiment

              Neutral
              Bullish 50% Bearish 50%

              Technicals

              SMA
              Positive
              20 days / 200 days
              Momentum
              8.89%
              12-Months-Change

              Fundamentals

              Return on Equity
              0.90%
              Trailing 12-Months
              Asset Growth
              2.52%
              Trailing 12-Months
              The Neurocrine Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Neurocrine

              Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis